Horizon Oncology Center Clinical Trial Participation
BREAST
Hoosier Oncology Group - COE01 Predicting Response and Toxicity in Patients
Receiving Chemotherapy for Breast Cancer: A Multicenter Genomic, Proteomic and Pharmacogenomic Correlative Study.
HOGCOE02: Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer: A Multicenter, Genomic, Proteomic and PharmacogenomicCorrelative Study
Hoosier Oncology Group BRE06-120 A Biological Sample Collection Protocol of Women With and Without Breast Cancer.
Hoosier Oncology Group BRE117 A Randomized, Double-Blind, Phase 2 Trial of Paclitaxel plus Bevacizumab and Placebo for Locally Recurrent or Metastatic Breast Cancer.
NSABP B-42 A clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer
A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast CancerTamoxifen versus Ovarian function suppression + tamoxifen versus Ovarian function suppression + exemestane
Program for the Assessment of Clinical Cancer Tests (PACCT-1):Trial Assigning Individualized Options for Treatment: The TAILORx Trial
LUNG
Hoosier Oncology Group HOG LUN04-77 A phase II study of Erlotinib with Bevacizumab in chemotherapy naïve Performance Status (PS) 2 patients with advanced Non-Small Cell Lung Cancer
Hoosier Oncology Group HOG LUN06-107 A Phase I/II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy With Sorafenib
Followed By Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC):
Genentech Protocol AVF3991: An observational study of Avastin (bevacizumab) in Combination With Chemotherapy for Treatment of Metastic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent.
Endocyte EC-FV-03: A Phase II Study of EC145 in Patients with Progressive Adenocarcinoma of the Lung.
HOG LUN06-116 Study Title: Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
MYLEODYSPLASTIC
Hoosier Oncology Group MDS04-85 A Phase II Randomized Trial with A Modified Dose and Schedule of Subcutaneously Administered Azacitidine and Erythropoietin versus Azacitidine Alone in Patients withLow-Risk Myelodysplastic Syndromes (Less than 11% Marrow and Peripheral Blood Blasts.
OVARIAN
Endocyte: EC-FV-02: A Phase II Study of EC145 in Patients with Advanced Ovarian and Endometrial Cancers
RENAL
ECOG 2805 A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma.
ECOG 2804: The Best Trial: A Randomized Phase II Study of VEGF, RAF kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib and Temsirolimus in Advanced renal Cell Carcinoma.
Miscellaneous Trials
Early diagnosis of Lung and Breast Cancer By Metabolomics-Based Methods
MD Anderson: PREVENTION OF CISPLATIN- OR OXALIPLATIN-INDUCED PERIPHERAL NEUROPATHY WITH ALPHA-LIPOIC ACID: A PLACEBO-CONTROLLED PHASE III TRIAL